<DOC>
	<DOCNO>NCT01398657</DOCNO>
	<brief_summary>This open-label randomized clinical study compare primary prostate cryoablation alone ( No-ADT group ) cryoablation plus short-term adjuvant androgen-deprivation therapy ( Adj-ADT group ) treatment patient high-risk localized prostate cancer .</brief_summary>
	<brief_title>Cryotherapy With Without Short-term Adjuvant Androgen-Deprivation Therapy Prostate Cancer</brief_title>
	<detailed_description>Subjects ( N=182 ) high-risk prostate cancer undergone primary prostate cryotherapy screen randomized 1:1 ratio receive either adjuvant ADT ( Adj-ADT ) No-ADT disease progression . Screening randomization do within four week cryoablation . Only assign Adj-ADT receive ADT total 12 month . PSA check every 3 month first year Cryo every 6 month thereafter . Long-term follow-up parameter include serum PSA protocol-mandated biopsy ( 36 month Cryo , irrespective PSA level recurrence document ) . For-cause biopsy also do post-Cryo PSA elevation reach Phoenix criterion ( Nadir + 2 ng/ml ) treat physician think necessary document tumor recurrence .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>1 . Age &gt; 20 year 2 . Histopathology proven prostate adenocarcinoma 3 . Nonmetastatic localize disease 4 . Prostate cancer deem highrisk recurrence ( PSA &gt; 20 ng/ml , Gleason score &gt; =8 , clinical stag &gt; =T2c ) 5 . Subjects undergone prostate cryoablation definitive treatment prior enrol study 6 . Subjects treat definitive treatment prostate cancer , include radical prostatectomy definitive radiotherapy . However , undergone focal prostate cryoablation cancer recurrence still eligible . 7 . Subjects may may receive neoadjuvant androgendeprivation therapy ( ADT ) form either castration ( medical ) and/or antiandrogens . Surgical castration ( orchiectomy ) allow . 8 . Subjects willing sign inform consent agree comply study procedures 1 . Those treated &gt; 8 week ( collectively continuously ) neoadjuvant ADT prior screen . 2 . Subjects cancer deem cure know less 5 year except basal cell carcinoma skin 3 . Other condition investigator think may affect subject compliance safety</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>localize</keyword>
	<keyword>High risk</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Randomized</keyword>
	<keyword>Cryotherapy</keyword>
	<keyword>Cryoablation</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Androgen Deprivation Therapy</keyword>
	<keyword>Hormone therapy</keyword>
	<keyword>ADT</keyword>
</DOC>